| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 17 | 100.7x | 17.3x | Bottom tier | |
Growth | 85 | 24.1% | 7.1% | Top tier | |
Quality | 23 | 0.4% | 4.5% | Bottom tier | |
Safety | 76 | — | 2.6x | Top tier | |
Capital Return | 3 | 0.00% | 0.06% | Bottom tier | |
Momentum | 43 | -24.1% | -1.6% | Around median | |
Sentiment | 82 | 10 | 3 | Top tier |
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Privia Health Group, Inc. operates a healthcare platform that brings together medical groups, risk-bearing entities, and practice technology and operational services. Its model supports providers through fee-for-service collections, revenue cycle management, and payer contracting, alongside value-based care programs that include shared savings, care management fees, and incentives; as of June 30, 2026, the network included 5,644 providers serving more than 6.1 million patients across more than 1,300 care centers in 25 states and the District of Columbia.
In fiscal Q2 2026, revenue was $632.6 million, gross profit was $11.8 million, net income was $9.0 million, and earnings per share were $0.07. Practice collections reached $970 million, up 12.4% year over year, while adjusted earnings before interest, taxes, depreciation, and amortization increased 29% to $37.4 million, with its margin equal to 28.3% of care margin after a year-over-year improvement of 310 basis points.
The value-based care mix expanded to more than 1.64 million attributed lives across more than 130 commercial and government programs, with estimated medical spending under management of approximately $15.7 billion. Commercial attributed lives reached 942 thousand, up 11.7%, while lives attributed to CMS Medicare programs increased 55%, Medicare Advantage by more than 12%, and Medicaid by more than 18%. According to trailing-twelve-month data through fiscal 2026, revenue was $2.4 billion and net income was $28.1 million.
The average analyst price target is $27.33 within a range of $24 to $32, with a consensus rating of “Buy.” The average is approximately 5.2% below the 52-week range high of $28.82, while the upper end of the target range exceeds that high by approximately 11%, and the eight-dollar target spread reflects meaningful variation in estimates of the profitability trajectory. This consensus must be weighed against the risks of the implied slowdown in collections, the timing of CMS settlements, and the absence of a specified timeline for reaching the high end of the margin target.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Practice collections reached $970 million in fiscal Q2 2026, up 12.4% year over year. The number of implemented providers increased 10.1% to 5,644, while lives attributed to value-based care programs increased 19.2%. This resulted in a 29% increase in adjusted earnings before interest, taxes, depreciation, and amortization to $37.4 million and a 310-basis-point improvement in its margin.
Privia brings together medical groups, risk-bearing entities, and a technology and services platform, and supports fee-for-service collections, revenue cycle management, and payer contracting. In value-based care, it helps physicians earn care management fees, shared savings, and incentives across commercial, Medicare, and Medicaid patients. On August 6, 2026, management estimated physician productivity gains at between 10% and 20%, and the total potential economic improvement for practices at between 15% and 50%.
As of June 30, 2026, the company managed more than 1.64 million attributed lives across more than 130 commercial and government programs. Commercial lives reached 942 thousand, up 11.7%, while lives in CMS Medicare programs increased 55%. Privia also estimated that its value-based arrangements manage approximately $15.7 billion in total medical spending, expanding the base for generating shared savings while also increasing cash flow sensitivity to government settlement schedules.
Automated analysis for informational purposes only — not investment advice.
Management stated on August 6, 2026 that it uses Gemini through the Google platform across multiple corporate functions and is testing applications in patient experience, clinical decision-making, and the revenue cycle. It also cited positive results from Navina in identifying potential medical conditions and coding compliance. The company measures time, outcomes, and costs saved for each workflow and links spending on these applications to its goal of increasing the adjusted earnings before interest, taxes, depreciation, and amortization margin from 28.3% of care margin in the quarter to a long-term range of between 30% and 35%.
Privia entered New Jersey in May 2026 through a partnership with Urology Group of Bergen County, which includes 25 practitioners, bringing its network to 25 states and the District of Columbia. Management stated on August 6, 2026 that the partnership's contribution to the fiscal 2026 outlook is small because of its size and timing. By contrast, it said that the IMS business in Arizona and Care Partners acquired from Evolent had integrated into the operating cadence and that their performance contributed to the updated outlook.
Management expected to convert 70% to 80% of fiscal 2026 adjusted earnings before interest, taxes, depreciation, and amortization into free cash flow, before any deployment of capital toward business development. However, CMS may delay the Medicare Shared Savings Program settlement results for 2025 performance until November 2026 because of proposed retroactive methodology changes. Privia explained that the impact on accounting accruals is limited, but the timing of receiving the settlement and making provider payments could alter the cash flow pattern at year-end.